解放军医药杂志Issue(8)：83-87,5.DOI:10.3969/j.issn.2095-140X.2015.08.021
维格列汀联合二甲双胍对超重2型糖尿病患者心血管疾病危险因素的干预作用
Intervention Effect of Vildagliptin Combined with Metformin on Risk Factors of Cardiovascular Disease in Over-weight Patients with Type 2 Diabetes Mellitus
摘要
Abstract
Objective To observe the intervention effect of Vildagliptin combined with Metformin on risk factors of cardiovascular disease in overweight type 2 diabetes mellitus patients, and to evaluate its efficacy and safety. Methods A total of 100 overweight patients with type 2 diabetes mellitus admitted during October 2013 and March 2014, who had failed to respond to Metformin therapy, were randomly divided into treatment group ( n =50 ) and control groups (n=50). All patients were given 500 mg/time Metformin orally (2/d) for 4 weeks, and then the control group was giv-en 1000 mg/time Metformin orally (2/d), while the treatment group was given 500mg/time Metformin (2/d) and 50 mg/time Vildagliptin (2/d) orally for 20 weeks. The changes of body mass index (BMI), waist circumference (W), systolic blood pressure (SBP), diastolic blood pressure (DBP), glycosylated hemoglobinA1c (HbA1c), fasting plasma glucose (FBG), 2 h postprandial blood glucose (2hPBG), total cholesterol (TC), triglyceride (TG), low-density lipo-protein cholesterol (LDL-C), C-reactive protein (CRP), homocysteine (Hcy) and incidence rate of the adverse reac-tions were compared before and after the treatment in the two groups. Results In 24 weeks after treatment, the levels of FBG, 2hPBG and HbA1c were significantly decreases compared with those before the treatment in the two groups ( P<0. 05), and the decreased levels in treatment group were more significant (P<0. 05); compared with those before the treatment, 24 weeks after treatment, the values of BMI, W and Hcy were significantly decreased in control group ( P<0. 05), and the values of BMI, W, SBP, blood fat, CRP and Hcy were significantly decreased in treatment group (P<0. 05), and the decreased levels in treatment group were more significant compared with those in control group (P<0. 05). The difference in incidence rate of adverse reactions was not statistically significant (P>0. 05). Conclusion Vildagliptin combined with Metformin in treatment of overweight patients with type 2 diabetes mellitus can effectively con-trol blood sugar and BMI without increasing the hypoglycemia risk, and at the same time it also can improve blood fat and reduce blood pressure with anti-inflammatory effect.关键词
维格列汀/二甲双胍/糖尿病,2型/超重/心血管疾病/危险因素Key words
Vildagliptin/Metformin/Diabetes mellitus, type 2/Overweight/Cardiovascular diseases/Risk factors分类
医药卫生引用本文复制引用
辛彩虹,李峥,洛伟光,王楠,旷劲松,薛晓馥..维格列汀联合二甲双胍对超重2型糖尿病患者心血管疾病危险因素的干预作用[J].解放军医药杂志,2015,(8):83-87,5.基金项目
沈阳市科技局高新技术产业发展与科技攻关计划项目(F11-262-9-25) （F11-262-9-25）
